Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer

被引:140
作者
Gugnoni, Mila [1 ]
Ciarrocchi, Alessia [1 ]
机构
[1] IRCCS Reggio Emilia, Azienda Unita Sanit Locale, Lab Translat Res, I-42122 Reggio Emilia, Italy
关键词
long noncoding RNAs (lncRNAs); Epithelial to Mesenchymal Transition (EMT); cancer; PROMOTES CELL-PROLIFERATION; INVASION-METASTASIS CASCADE; BREAST-CANCER; UP-REGULATION; LUNG-CANCER; INHIBITS PROLIFERATION; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; ACTIVE CHROMATIN; GENE-EXPRESSION;
D O I
10.3390/ijms20081924
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Epithelial-mesenchymal transition (EMT) is a multistep process that allows epithelial cells to acquire mesenchymal properties. Fundamental in the early stages of embryonic development, this process is aberrantly activated in aggressive cancerous cells to gain motility and invasion capacity, thus promoting metastatic phenotypes. For this reason, EMT is a central topic in cancer research and its regulation by a plethora of mechanisms has been reported. Recently, genomic sequencing and functional genomic studies deepened our knowledge on the fundamental regulatory role of noncoding DNA. A large part of the genome is transcribed in an impressive number of noncoding RNAs. Among these, long noncoding RNAs (lncRNAs) have been reported to control several biological processes affecting gene expression at multiple levels from transcription to protein localization and stability. Up to now, more than 8000 lncRNAs were discovered as selectively expressed in cancer cells. Their elevated number and high expression specificity candidate these molecules as a valuable source of biomarkers and potential therapeutic targets. Rising evidence currently highlights a relevant function of lncRNAs on EMT regulation defining a new layer of involvement of these molecules in cancer biology. In this review we aim to summarize the findings on the role of lncRNAs on EMT regulation and to discuss their prospective potential value as biomarkers and therapeutic targets in cancer.
引用
收藏
页数:25
相关论文
共 191 条
[1]   C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector [J].
Abudayyeh, Omar O. ;
Gootenberg, Jonathan S. ;
Konermann, Silvana ;
Joung, Julia ;
Slaymaker, Ian M. ;
Cox, David B. T. ;
Shmakov, Sergey ;
Makarova, Kira S. ;
Semenova, Ekaterina ;
Minakhin, Leonid ;
Severinov, Konstantin ;
Regev, Aviv ;
Lander, Eric S. ;
Koonin, Eugene V. ;
Zhang, Feng .
SCIENCE, 2016, 353 (6299)
[2]   Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology [J].
Alter, J ;
Lou, F ;
Rabinowitz, A ;
Yin, HF ;
Rosenfeld, J ;
Wilton, SD ;
Partridge, TA ;
Lu, QL .
NATURE MEDICINE, 2006, 12 (02) :175-177
[3]   EMT: 2016 [J].
Angela Nieto, M. ;
Huang, Ruby Yun-Ju ;
Jackson, Rebecca A. ;
Thiery, Jean Paul .
CELL, 2016, 166 (01) :21-45
[4]  
[Anonymous], 2016, SCI REP
[5]   Therapeutic Targeting of Long Non-Coding RNAs in Cancer [J].
Arun, Gayatri ;
Diermeier, Sarah D. ;
Spector, David L. .
TRENDS IN MOLECULAR MEDICINE, 2018, 24 (03) :257-277
[6]   Aptamers as Both Drugs and Drug-Carriers [J].
Ashrafuzzaman, Md. .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[7]   A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition [J].
Beltran, Manuel ;
Puig, Isabel ;
Pena, Cristina ;
Miguel Garcia, Jose ;
Belen Alvarez, Ana ;
Pena, Raul ;
Bonilla, Felix ;
Garcia de Herreros, Antonio .
GENES & DEVELOPMENT, 2008, 22 (06) :756-769
[8]   Long Noncoding RNA and Cancer: A New Paradigm [J].
Bhan, Arunoday ;
Soleimani, Milad ;
Mandal, Subhrangsu S. .
CANCER RESEARCH, 2017, 77 (15) :3965-3981
[9]   Application of aptamers for in vivo molecular imaging and theranostics [J].
Bouvier-Mueller, Alix ;
Duconge, Frederic .
ADVANCED DRUG DELIVERY REVIEWS, 2018, 134 :94-106
[10]   EMT in cancer [J].
Brabletz, Thomas ;
Kalluri, Raghu ;
Angela Nieto, M. ;
Weinberg, Robert A. .
NATURE REVIEWS CANCER, 2018, 18 (02) :128-+